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ABSTRACT 
 
Introduction: Pharmacological options to address the imbalance between bone resorption and 
accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique biologic 
pathways such as :QWȕ-catenin pathway have been targeted in the quest for new emerging 
therapeutic strategies.  
Areas Covered: This review aims to provide an overview of existing pharmacotherapy for 
osteoporosis in women and explore state-of±the-art and emerging therapies to prevent bone loss, 
with an emphasis on the mechanism of action, indications and side effects. 
Expert Opinion: Bisphosphonates appear to be a reliable and cost-effective option, whereas 
denosumab has introduced a simpler dosing regimen and may achieve a linear increase in BMD 
with no plateau being observed, along with continuous anti-fracture efficacy. Selective estrogen 
receptor modulators (SERMs) are synthetic non-steroidal agents which have 
varying estrogen agonist and antagonist activities in different tissues and antifracture efficacy. 
Abaloparatide, a parathyroid-hormone-related peptide (PTHrP)-analogue, approved by the FDA 
in April 2017, constitutes the first new anabolic osteoporosis drug in the US for nearly 15 years 
and has also proven its anti-fracture efficacy. Romosozumab, a sclerostin inhibitor, which induces 
bone formation and suppresses bone resorption, has also been developed and shown anti-fracture 
efficacy; however, concerns have arisen with regard to increased cardiovascular risk.  
 
 
Keywords: osteoporosis, anti-resorptive medications, osteoanabolic agents, abaloparatide, 
sclerostin, romosozumab 
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1. Introduction 
 
Osteoporosis is a metabolic bone disease characterized by an imbalance between bone resorption 
and accrual, resulting in microarchitectural disruption, reduced bone mineral density (BMD) and 
skeletal fragility[1]. Fragility fractures are common in the osteoporotic population and occur from 
forces not ordinarily resulting in fracture. The most common sites are the vertebral column, hip 
and wrist; however, fragility fractures of the humerus, pelvis and ribs are not uncommon[1]. 
Over the past decades, several medications with different mechanisms of action have been 
employed for the treatment and prevention of osteoporosis. Current pharmacological options 
include anti-resorptive and osteoanabolic agents as well as drugs with dual action.  Anabolic agents 
are intended to inverse the imbalance of bone remodeling and stimulate bone formation, therefore 
increasing BMD; represented predominantly by teriparatide and abaloparatide.  
On the other hand, anti-resorptive medications try to address the imbalance between bone 
resorption and accrual. They aim to inhibit bone resorption by decreasing bone turnover or 
disrupting osteoclast proliferation and maturation and include five principal classes of agents; 
bisphosphonates, selective estrogen receptor modulators (SERMs), estrogens, denosumab 
(monoclonal antibody) and calcitonin[2]. 
Most of the current pharmacological strategies are principally based on bone anti-resorptive 
agents. In clinical practice, bisphosphonates (alendronate, risedronate, ibandronate, zoledronic 
acid) are utilized as first-line treatments since they constitute cheap and reliable agents, which are 
effective in reducing vertebral, non-vertebral and hip (except for ibandronate) fracture risk [3]. 
Denosumab is an anti-RANKL monoclonal antibody suppressing bone resorption with high and 
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continuous anti-fracture efficacy[3,4]. Selective estrogen receptor modulators (SERMs) are 
synthetic non-steroidal agents which have varying estrogen agonist and antagonist activities in 
different tissues and antifracture efficacy [3]. On the other hand, anabolic agents stimulate bone 
formation and reserved for high fracture risk individuals, providing vertebral and non-vertebral 
anti-fracture efficacy [5]; they are represented predominantly by teriparatide, a human 
recombinant parathyroid hormone (PTH), and abaloparatide, a synthetic PTH-related peptide 
(PTHrP) analogue. 
New emerging therapeutic strategies target unique ELRORJLFSDWKZD\VVXFKDVWKH:QWȕ-catenin 
pathway[6]. These strategies have the potential to substantially decrease bone resorption and be 
more effective in fracture reduction in osteoporotic patients.  
This review maps out existing pharmacotherapy for osteoporosis in women with an emphasis on 
the mechanism of action and the state-of-the-art therapies to prevent bone loss. Our review also 
explores emerging pharmacological strategies and touches upon the future direction in the field. 
 
2.1 Anti-resorptive medications 
2.1.1 Bisphosphonates  
Bisphosphonates are structurally linked to inorganic pyrophosphate, a naturally occurring 
compound consisting of two phosphate groups[7].Like pyrophosphate, bisphosphonates have 
demonstrated a very high affinity for hydroxyapatite crystals and are predominantly embedded in 
sites of augmented skeletal turnover[7]. 
First generation bisphosphonates (etidronate, clodronate, tiludronate) are characterized by non-
nitrogen containing agents and have a distinct mechanism by which osteoclast apoptosis is 
fostered. Owing to their structural similarity to pyrophosphate, they become embedded in 
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adenosine triphosphate (ATP) molecules following osteoclast-mediated uptake[8].  Consequently, 
a high concentration of the above-mentioned ATP analogues exhibits a cytotoxic effect on 
osteoclasts, eventually promoting osteoclast apoptosis.  
The second and third generation of bisphosphonates utilized for the treatment and prevention of 
osteoporosis (alendronate, pamidronate, ibandronate, risedronate and zoledronic acid) share a 
structural similarity since they have nitrogen-containing R2 side chains[7]. Their anti-resorptive 
effect results from the inhibition of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the 
mevalonic acid pathway. The mevalonate pathway is critical in regulating the production of 
isoprenoid lipids and sterols employed for the isoprenylation (post-translational modification) of 
GTP-binding proteins which play central roles in osteoclast function[7,9,10]. As a result, their 
anti-resorptive potency lies in their ability to promote osteoclast apoptosis. 
Bisphosphonate potency is largely dependent on their activity to inhibit farnesyl pyrophosphate 
synthase; the rank order of potency is zoledronate>risedronate>> ibandronate > alendronate[11]. 
Bisphosphonates also differ in their bond strength to the mineral matrix, with zoledronic acid 
demonstrating the highest affinity to hydroxyapatite crystals[7], followed by alendronate, 
ibandronate and risedronate[12].Biochemical markers of bone turnover that reflect the activity of 
bone cells and hence can be utilised to measure bisphosphonate efficacy in the clinical setting, 
include bone resorption markers; mainly the degradation products of type I collagen, serum C-
telopeptide of type I collagen (sCTX-1) and urine (uNTX) or serum N-terminal telopeptide (serum 
NTX), as well as bone formation markers, such as isoenzyme of alkaline phosphatase and serum 
type 1 procollagen (C-terminal or N-terminal) peptides C1NP or P1NP, respectively. 
Owing to their unique mechanism of action and long halve-lives, bisphosphonates are accumulated 
and released from the skeleton for a long time after treatment is ceased. Notwithstanding technical 
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challenges in estimating bisphosphonate levels in serum and urine, studies have reported a slow 
elimination phase with an estimated biologic half-life greater than ten years following intravenous 
administration of high doses of alendronate[13]. The fact that they can protect an individual for an 
additional 3-5 years[10] has been the basis of advocaWLQJDµ¶GUXJKROLGD\¶¶DIWHU-10 years of 
continuous administration[14]. However, recommendations are to be individualized to each 
SDWLHQW¶VFOLQLFDOSLFWXUH$VUHIOHFWHGE\LQWHUQDWLRQDOJXLGHOLQes, such as those released by the 
American Society for Bone and Mineral Research (ASBMR), and the European Menopause and 
Andropause Society[15] risk should be stratified in women following five years of alendronate or 
three years of intravenous bisphosphonate therapy[16]. High-risk postmenopausal women should 
continue BP therapy since the benefit deriving from fracture risk reduction greatly outweighs the 
ULVN RI VHULRXV DGYHUVH HYHQWV )RU ZRPHQ FRQVLGHUHG RI ORZ ULVN D ³GUXJ KROLGD\´ FDQ EH
considered, with periodic risk assessment[16]. 
All currently approved bisphosphonates are indicated for osteoporosis treatment and fracture 
prevention; namely reducing the incidence of spinal fractures. Alendronate, risedronate and 
zoledronic acid have also demonstrated efficacy in preventing hip and non-vertebral fractures, 
contrary to ibandronate [17]. Their indications and approved dosing can be found in Table 1. 
A recently published systematic review and network meta-analysis encompassing thirty-six 
primary studies concluded that zoledronic acid demonstrated comparative efficacy in preventing 
vertebral and non-vertebral fractures, whereas both alendronate and zoledronic acid were the most 
effective in preventing hip fractures [18]. Results were concordant with a previously published 
comparative network meta-analysis reporting that zoledronic acid showed the highest overall 
probability of protecting from any fracture [19]. 
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The commonest side effects include gastrointestinal irritation and acute phase reaction with 
intravenous administration, although they are frequently mild in severity[12]. Uncommon side 
effects involve musculoskeletal pain, while it has been suggested, that albeit rare, osteonecrosis of 
the jaw (ONJ) and atypical femoral bone fractures (AFFs) represent serious complications 
associated with long-term use of nitrogen bisphosphonates. However, the incidence of AFFs 
among patients receiving bisphosphonates is low, and a causal relationship has yet to be 
established. Owing to their rarity, none of the long-term trials was statistically powered to evaluate 
differences in the incidence of ONJ or AFFs. 
 
2.1.2 Denosumab 
Osteoclasts originate from cells of the monocyte/macrophage lineage upon stimulation of two 
major modulators of osteoclast formation, the monocyte/macrophage colony-stimulating factor 
(M-CSF) and the receptor activator of NF-ɤ% OLJDQG 5$1./ D W\SH , WUDQVPHPEUDQH
protein[20]. Other regulatory molecules involve cytokines and hormones such as PTH, 
prostaglandin E2, calcitriol, thyroxine, and interleukin-1 (IL-1) [21±23]. M-CSF binds to its 
receptor on the osteoclast, c-fms (colony-stimulating factor 1 receptor), a transmembrane tyrosine 
kinase-receptor, ameliorating survival and proliferation of osteoclast precursors [20,24]. However, 
the receptor activator of nuclear factor-ț%OLJDQG5$1./LVFRQVLGHUHGWR represent the primary 
osteoclast differentiation factor. RANKL, a type II transmembrane protein [25], belongs to the 
TNF (Tumour Necrosis Factor) ligand family and binds to RANK to stimulate the differentiation 
and multiplication of osteoclasts [25,26]. In more detail, RANKL activates c-Fos, a transcription 
factor, that in turn precipitates a chain reaction eventually leading to osteoclast differentiation and 
apoptosis inhibition [25]. Osteoprotegerin (OPG) is a soluble decoy receptor expressed in 
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osteoblasts and other tissues, such as spleen and bone marrow [25]. The role of the OPG in the 
bone resorption regulation lies in its ability to inhibit RANK/RANKL interaction, therefore 
inhibiting osteoclast differentiation and protecting from excessive bone resorption. Therefore, 
OPG and RANKL are competitors in the molecular milieu, with high OPG concentrations exerting 
an inhibitory effect on the RANK ± RANKL signalling pathway. 
Denosumab is an IgG2 monoclonal antibody that suppresses bone resorption by mimicking the 
action of OPG in bone microenvironment and has been approved for fracture treatment and 
prevention of osteoporosis. In particular, denosumab is used for preventing spinal, hip and non-
vertebral fractures. Denosumab binds to RANKL preventing its binding to RANK, hence reducing 
osteoclast proliferation, survival and bone resorption. Its chemical structure consists of four chains; 
two heavy chains consisting of 448 amino acids with four intramolecular disulfides and two light 
chains consisting of 215 amino acids [27]. Alike other monoclonal antibodies, denosumab has 
demonstrated non-linearity in its pharmacokinetics dependent on the dose. It is characterized by a 
unique biochemical profile of prolonged absorption and ȕSKDVH whereas the terminal phase is 
more rapid [27]. 
A pooled analysis of 22,944 serum denosumab concentrations  in 1,564 subjects defined the 
subcutaneous bioavailability of denosumab to be 64% DQGWKH5$1./GHJUDGDWLRQUDWH(?K-
1 [28]. The first-order absorption rate constant (ka) utilized to characterize absorption was 
determined to be ka=(?K-1 [28]. Dosing adjustment based on the SDWLHQW¶V EDVHOLQH
characteristics is not deemed necessary as the non-linear pharmacokinetic profile is probably 
attributed to RANKL binding [28]. Pharmacokinetic and pharmacodynamic properties of different 
antiresorptive agents are presented in Table 2. 
10 
 
Denosumab is administered subcutaneously at a dose of 60mg once every six months. Available 
higher-level research evidence supports the superiority of denosumab against other anti-
osteoporotic drugs. In a dose-response-based meta-analysis encompassing 142 RCTs, denosumab 
demonstrated greater BMD gains compared with other drug classes; namely alendronate, 
risedronate, zoledronic acid, ibandronate, raloxifene and calcitonin [29]. In concordance, a 
recently published meta-analysis involving 2,968 non-naïve patients reported superiority of 
denosumab in augmenting BMD at all skeletal sites measured compared with other anti-
osteoporotic drugs [30]. Owing to its dosing frequency and regimen simplicity, denosumab has 
also achieved higher persistence rates compared with bisphosphonates [31±33]. 
A unique characteristic of denosumab is that no apparent plateau in BMD gains has been 
demonstrated in the numerous trials so far. The FREEDOM (Fracture Reduction Evaluation of 
Denosumab in Osteoporosis Every Six Months) was the largest phase III registration trial for 
studying denosumab. It included of 7,808 postmenopausal women with lumbar spine BMD T-
scores < 2.5 that were randomly assigned to 60 mg denosumab / 6 monthly or placebo for three 
years [34]. The reported results unveiled a relative risk reduction (RRR) in the incidence of new 
vertebral fractures of 68%, p < 0.0001, while denosumab also reduced hip and non-vertebral 
fractures (RRR 40%, p < 0.04 and RRR 20%, p < 0.01)[34]. Recently published results revealed 
that ten years of denosumab administration resulted in a linear increase in lumbar spine BMD 
accounting for a cumulative 21.7% increase [35]. 
Unlike bisphosphonates, denosumab is not characterised by a long biologic half-life nor is it 
incorporated into the bone; hence its antiresorptive effect ceases after suspension of treatment. 
Several reports have described cases of multiple vertebral fractures upon discontinuation of 
denosumab, raising concerns about a rebound in bone turnover and BMD losses [36±39]. 
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Following a systematic review of reported case series and a renewed analysis of the FREEDOM 
and FREEDOM Extension Trial, recommendations were issued by a working group formed by the 
European Calcified Tissue Society (ECTS); re-stratification of risk should be performed after five 
years of administration and denosumab cessation should not be considered without alternative 
osteoporosis treatment[40].  
Owing to the GUXJ¶VSKDUPDFRORJLFDOmechanism of action, concerns had been raised regarding 
the potentiality to provoke immunosuppression and immune system dysfunction. According to 
post-market safety surveillance reports, serious adverse reactions involved AFFs, ONJ, severe 
symptomatic hypocalcemia (SSH) and anaphylaxis (Table 3) [41]. Four cases were adjudicated as 
consistent with AFF while another 32 were consistent with the ONJ, with the exposure to 
denosumab estimated at 1,252,566 patient-years. Anaphylaxis occurred in five patients with no 
fatal outcomes reported. In eight study subjects, SSH was evident, with chronic kidney disease 
identified as a risk factor in this group [41]. Of note, none of the existing RCTs has reported a 
higher incidence of AFF or ONJ with the administration of denosumab and a causal relationship 
has not been established yet. 
 
2.1.3 Selective estrogen receptor modulators (SERMS) 
 
Estrogen receptors are found both in osteoclasts and osteoblasts, contributing to bone remodelling 
regulation. It has been established that estrogen deficiency increases bone resorption  [42]. The 
exact mechanism seems to be mediated by T-cells, which in an estrogen deplete-state, increase the 
secretion of tumor necrosis factor (TNF)±alpha, interleukin-6 (IL-6) and IL-1 [22,23,43]. These 
cytokines, in turn, enhance the production of RANKL and M-CSF [44] amplifying 
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osteoclastogenesis and osteoclast differentiation. Recent studies demonstrated that 
the intestinal microbiota modulates inflammatory responses caused by sex steroid deficiency, 
leading to trabecular bone loss. Estrogen depletion increased the permeability of the gut expanding 
Th17 cells, and upregulating WKHRVWHRFODVWRJHQLFF\WRNLQHV71)Į7NF), RANKL, and IL-17 in 
the small intestine and bone marrow in murine models [a]. 
 
[a] Li JY, Chassaing B, Tyagi AM, et al. Sex steroid deficiency-associated bone loss is microbiota 
dependent and prevented by probiotics. J Clin Invest. 2016 Jun 1;126(6):2049-63.  
 
Overcoming estrogen depletion emerged as another promising pharmacological target for the 
treatment and prevention of osteoporosis in post-menopausal women. Over the past decade, 
SERMs have been intensively studied [45]. They are synthetic, structurally different non-steroidal 
agents that have tissue-specific estrogen receptor agonist or antagonist activity in varying 
magnitudes. Their biological activity is mainly attentive to ER-alpha (ER-D) and ER-beta (ER-E) 
subtypes for the ER family. ER-D is expressed in a greater tissue variety and is considered to be 
the principle ER expressed in bone tissue, whereas ER-E is mainly expressed in the ovaries, 
prostate and lungs [46]. SERMs exhibit different affinity properties, resulting in unique 
agonist/antagonist effects[47±49]. Notably, most SERMS exert estrogen-agonistic effects on bone 
and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. 
In particular, by binding to estrogen receptors in bone tissues, SERMs interfere with bone 
homeostasis by down-modulating the activity of osteoclasts in a transforming growth factor-ȕ-
dependent manner leading to reduced bone resorption [50]. 
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SERMs have been studied as a subject of great scientific interest, due to their theoretical ability to 
retain the beneficial effects of oestrogens while eliminating unwanted side-effects related to 
oestrogen-receptor binding in non-targeted tissues. There are two main classes of agents used in 
clinical practice: a) the triphenylethylene derivatives, tamoxifen and toremifene, which are 
employed for the treatment of breast cancer and b) raloxifene (benzothiophene derivative), 
bazedoxifene and lasofoxifene (naphthalene derivative), which are indicated for the prevention 
and treatment of osteoporosis [51]. 
Raloxifene, a second-generation SERM, has been established as a third-line treatment for the 
secondary prevention of osteoporotic fragility fractures in postmenopausal women [52], excluding 
hip and non-vertebral fractures. Further development of SERM compounds, led to another 
generation of SERMs with comparable chemical and molecular structure to raloxifene but 
optimised side-effect profile named as bazedoxifene (TSE-424) and lasofoxifene (CP-336156) 
[45].   
In the 1990s, the idea of combining bazedoxifene with conjugated estrogen was introduced aiming 
to achieve greater estrogenic and anti-estrogenic effects than either of the components alone. The 
latter combination resulted in the introduction of a new classification named as tissue selective 
estrogen complex (TSEC) [53,54]. Phase III RCTs exploring the combination of bazedoxifene 
with conjugated estrogens in healthy post-menopausal women with osteoporosis have confirmed 
the aforementioned superiorities, showing improvement in vasomotor symptoms and little or no 
stimulation of breast or endometrium oestrogen receptors (ER) [55,56].  
The incidence of new vertebral fractures in post-menopausal women with diagnosed osteoporosis 
(n=7,492), was significantly lower with bazedoxifene 20 mg (2.3%), bazedoxifene 40 mg (2.5%), 
than placebo (4.1%), and comparable to raloxifene 60 mg (2.3%), as demonstrated by a 3-year 
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phase III RCT [57]. Interestingly, secondary endpoints of the above study showed that 
bazedoxifene (with or without conjugated estrogen) also had a positive effect on lumbar spine 
BMD in healthy post-menopausal women, compared with placebo groups, which was maintained 
after five to seven years of treatment [58]. Bazedoxifene has been approved by the European 
Medicines Agency (EMA) for the treatment of osteoporosis in 2009, while the U.S. Food and Drug 
Administration (FDA) granted approval of bazedoxifene with conjugated estrogen as a 
combinational drug in 2013, for the prevention of postmenopausal osteoporosis and vasomotor 
symptomatology. 
Lasofoxifene has been described as another 3rd generation SERM, with comparable clinical effects 
to bazedoxifene. Lasofoxifene demonstrates high-affinity selective binding to both ERĮ and ERȕ 
receptors [59]. Unlike bazedoxifene, it is characterized by a remarkable oral bioavailability, which 
is attributed to increased resistance in intestinal wall glucuronidation [60,61]. Lasofoxifene has 
demonstrated linear pharmacokinetics over a wide dose range (from 0.01 to 100 mg/d), and 
interestingly a Cmax of ~ 6 hours. Elimination has also been studied, and terminal elimination 
half-life (t1/2) has been estimated to be reached at day 6 [62].  
Dosing regimens were compared in a phase II RCT were BMD increase was measured as a 
biomarker with both doses of lasofoxifene, compared with baseline ( increases of 1.8% and 2.2% 
for 0.25 mg and 1.0 mg/day, respectively, p DQGwith placebo (3.6% and 3.9% for 0.25 
mg and 1.0 mg/day, respectively, p  [61]. Lasofoxifene has been evaluated in multiple phase 
III clinical trials including the PEARL [63] (Postmenopausal Evaluation and Risk Reduction With 
Lasofoxifene), OPAL [64] (Osteoporosis Prevention and Lipid-Lowering study), CORAL [61] 
(Comparison of Raloxifene and Lasofoxifene trial), where it repetitively demonstrated an 
improvement in bone mass and a reduction in the risk of vertebral and non-vertebral fractures. As 
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concluded after the completion of all the aforementioned trials, lasofoxifene, demonstrated a dose-
related optimized side effect profile compared to placebo. The RRR in the absolute incidence of 
invasive breast cancer was 85% for 0.5 mg/day (p<0.05), 21% for 0.25 mg/day (p>0.1) and for the 
incidence of major coronary heart disease 1.8% for 0.5 mg/day p<0.05 and 2.4% for 0.25mg/day 
p>0.1[65].In line with the risk of deep vein thrombosis (DVT) pertaining to estrogen replacement 
regimens, lasofoxifene was associated with an approximately 2-fold increased risk of DVT, as 
evidenced by the findings of the PEARL study follow-up. In fact, pulmonary embolism occurred 
less frequently than deep vein thrombosis (0.2% vs 0.8%, respectively) but was also significantly 
increased in patients treated with the active drug compared with placebo [hazard ratio (HR): 4.49, 
95% confidence interval (CI), 0.97±20.79 for lasofoxifene 0.5 mg/d and HR: 5.98, 95% CI, 1.33±
26.72 for lasofoxifene 0.25 mg/d] [66]. 
To date, the FDA has yet to approve the use of lasofoxifene following the last rejection in January 
2009. Nevertheless, EMA approved its use for the treatment of osteoporosis-related fractures in 
post-menopausal women, the same year. This followed by a cessation of the validity of 
the marketing authorization in 2012 as lasofoxifene had not been marketed in Europe since its 
initial marketing authorization. 
 
 
2.2 Anabolic agents 
 
Anabolic agents stimulate bone formation and are represented predominantly by teriparatide, a 
human recombinant parathyroid hormone (PTH) containing the first 34 amino acids of the 
endogenous hormone, and abaloparatide, a synthetic PTH-related peptide (PTHrP) analogue. The 
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biological activities of PTH and PTHrP analogues on bone are mediated through activation of the 
parathyroid hormone 1 receptor (PTH1R) [73], a G-protein coupled receptor with two different 
high-affinity conformations R0 and RG, expressed in a plethora of tissues including osteoblasts 
and osteoclasts [74].Notably, osteoanabolic potency has been demonstrated only with intermittent 
administration of PTH and PTHrP analogues, whereas continuous stimulation of PTH1R has been 
shown to augment bone turnover and consequently result in bone resorption [75]. In the clinical 
setting, teriparatide has reportedly led in spine and hip BMD gains, vertebral and non-vertebral 
risk reduction in postmenopausal women, as well as in men and individuals suffering from 
glucocorticoid-induced osteoporosis [76].  The recent VERO study demonstrated also that 
teriparatide was significantly more effective in reducing the new vertebral fractures compared to 
alendronate after 24 months therapy in postmenopausal women with severe osteoporosis meaning 
at least two moderate or one severe vertebral fracture and a BMD T score of less than or equal to 
-1·50 [b]. 
[b] Kendler DL, Marin F, Zerbini CAF et al. Effects of teriparatide and risedronate on new 
fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-
blind, double-dummy, randomised controlled trial. Lancet. 2018 Jan 20;391(10117):230-240.  
Abaloparatide is a selective activator of the PTH1R, exhibiting a higher selectivity to the RG 
confirmation than teriparatide [77]. The aforementioned difference is translated into a more 
transient response to ligand binding [74], hence minimizing stimulation of bone resorption. Initial 
attempts at evaluating the therapeutic potential of abaloparatide in animal studies unveiled 
encouraging results. Abaloparatide exhibited its osteoanabolic potency by increasing bone 
formation and BMD gains both in ovariectomized rats and ovariectomized cynomolgus monkeys 
[78,79].  Subsequently, as the agent moved swiftly from animal to human trials, concordant results 
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were reported. A phase II multicentre, double-blind, RCT investigated the efficacy and safety of 
various dosing regimens of abaloparatide, against teriparatide and placebo [80]. Upon comparison 
of abaloparatide with placebo, significant BMD gains were reported in total hip and lumbar spine 
with the 40- and 80-ȝJRQFHGDLO\UHJLPHQVDQGLQIHPRUDOQHFN%0'ZLWKWKH-ȝJUHJLPHQ
Notably, abaloparatide was superior to teriparatide in augmenting total hip BMD [80].  
With regard to clinically translatable outcomes, the Abaloparatide Comparator Trial in Vertebral 
Endpoints (ACTIVE) Trial, a phase III, double-blind RCT, evaluated the effect of abaloparatide, 
teriparatide and placebo on the incidence of new vertebral fractures and BMD changes[81]. Both 
active agents demonstrated superiority against placebo in reducing fractures and augmenting BMD 
at all skeletal sites studied. When compared with teriparatide, the 80-ȝJUHJLPHQGHPRQVWUDWHGQR
difference concerning efficacy endpoints, albeit the incidence of hypercalcemia was lower [81]. 
Finally, abaloparatide received approval for the treatment of postmenopausal osteoporosis by the 
FDA in April 2017 constituting the first new anabolic osteoporosis drug in the US for nearly 15 
years [82]. EMA however, refused at the moment approval of the abaloparatide for the treatment 
of postmenopausal osteoporosis having mainly concerns about the effectiveness of the drug in the 
prevention of non-vertebral fractures and possible effects on heart function as the increase in the 
heart rate and palpitations. 
Interestingly, several RCTs have attempted to adjudicate the effect of combining PTH analogs 
with other active agents. When compared with alendronate and PTH monotherapy, the 
combination of both failed to show any additive BMD increase [83]. In contrast, the Denosumab 
and Teriparatide Administration (DATA) study proved combined denosumab and teriparatide 
therapy to be superior to either agent alone[84]. With regard to abaloparatide, an extension of the 
ACTIVE trial was designed to assess the effect of the concurrent administration of alendronate in 
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patients previously treated wither with abaloparatide or placebo. Results confirmed that gains in 
BMD and RRR increased even further for the abaloparatide/alendronate group compared with the 
placebo/alendronate group[85].    
 
3. Sequential therapy 
In general, the optimal therapeutic strategy after discontinuation of an anti-osteoporotic therapy, 
has not been established. However, several data have emerged and are presented as follows. 
 
3.1. Anti-resorptive after osteo-anabolic therapy 
The sequential therapy with anti-resorptive agents has been evaluated to test the BMD gain 
following the cessation of anabolic therapy. Alendronate led to a further increase in BMD, 
especially in the trabecular bone after completion of PTH (1-84) therapy [c]. Raloxifene also 
showed a beneficial effect in maintaining lumbar spine and increasing hip BMD after one year of 
teriparatide therapy [d]. The ACTIVExtend study was the first to test as the primary end-point, the 
incidence of vertebral and nonvertebral fractures and changes BMD of the sequential 
administration of an anti-resorptive agent (alendronate) after completion of the prespecified 
therapy of an anabolic compound. Abaloparatide followed by alendronate regimen effectively 
reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and increased 
BMD compared with placebo followed by alendronate  [e]. 
 
 [c] D.M. Black, J.P. Bilezikian, K.E. Ensrud, et al., One year of alendronate after one year of 
parathyroid hormone (1-84) for osteoporosis, N Engl J Med 353(6) (2005) 555-65. 
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 [d] R. Eastell, T. Nickelsen, F. Marin, et al., Sequential treatment of severe postmenopausal 
osteoporosis after teriparatide: final results of the randomized, controlled European Study of 
Forsteo (EUROFORS), J Bone Miner Res 24(4) (2009) 726-36. 
[e] H.G. Bone, F. Cosman, P.D. Miller, et al., ACTIVExtend: 24 months of alendronate after 18 
months of abaloparatide or placebo for postmenopausal osteoporosis, J Clin Endocrinol Metab 
103(8) (2018) 2949-2957. 
 
 
3.2. Osteo-anabolic after anti-resorptive therapy 
Teriparatide treatment for 24 months significantly increased the BMD in patients with and 
without previous antiresorptive therapy use [f,g]. Prior antiresorptive agent treatment, 
however, especially those of longer skeletal half-lives, modestly blunted the expected 
BMD response to teriparatide [f] but this has not been confirmed in all studies [g]. Romosozumab 
has also been evaluated in women previously treated with bisphosphonates for at least three years, 
in a head-to-head comparison with teriparatide. Romosozumab induced significantly greater hip 
BMD changes compared with teriparatide at one-year follow-up [h].  
 
[f] B.M. Obermayer-Pietsch, F. Marin, E.V. McCloskey, et al., Effects of two years of daily 
teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and 
without prior antiresorptive treatment, J Bone Miner Res 23(10) (2008) 1591-600. 
[g] S. Boonen, F. Marin, B. Obermayer-Pietsch, et al., Effects of previous antiresorptive therapy 
on the bone mineral density response to two years of teriparatide treatment in postmenopausal 
women with osteoporosis, J Clin Endocrinol Metab 93(3) (2008) 852-60. 
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[h] B.L. Langdahl, C. Libanati, D.B. Crittenden, et al., Romosozumab (sclerostin monoclonal 
antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral 
bisphosphonate therapy: a randomised, open-label, phase 3 trial, Lancet 390(10102) (2017) 1585-
1594. 
 
 
2.3 Emerging therapies  
2.3.1 Anabolic agents with antiresorptive properties 
 
Sclerostin ± an osteocyte secreted glycoprotein coded for by the SOST gene [17q12-q21] - is a key 
regulator of osteoblast differentiation and function [6]. It binds to LRP-5/6 co-receptors preventing 
interactions between Wnt and its receptor, ultimately, leading to phosphorylation and degradation 
of ß-catenin [101]. As a result, Wnt target genes are not activated, downregulating the canonical 
Wnt singling pathway responsible for osteoblast differentiation, proliferation and function[86]. 
Notably, sclerostin has also been shown to promote osteoclast formation through a RANKL-
dependent pathway [102]. From a clinical perspective, a study of patients with sclerostin genetic 
deficiency (van Buchem disease) found that patients had increased bone mass, strength and 
reduced fracture rates, corroborating the importance of sclerostin in bone metabolism [103]. The 
synthesis of molecular and clinical evidence rendered sclerostin blocking with a monoclonal 
antibody an attractive therapeutic target for osteoporosis. 
Since then, three monoclonal antibodies have been developed: romosozumab (AMG-785), 
blosozumab (LY251546) and BPS804 [98]. Animal studies with romosozumab in ovariectomized 
rats and primates showed increases in bone mass and strength owing to the increased bone 
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formation and reduced resorption [104,105]. Early human trials of romosozumab showed that the 
agent reaches peak serum concentration within a week, demonstrating a high binding affinity for 
sclerostin while displaying non-linear kinetics with biphasic elimination (t1/2=11-18 and 6-7 days) 
[106±108]. 
A Phase II RCT investigated the efficacy and safety of various dosing regimens of romosozumab 
against placebo, alendronate and teriparatide in post-menopausal women with low BMD [109]. 
When compared with placebo and active comparators, the 140mg and 210mg once monthly dosing 
regimens of romosozumab were significantly better in increasing lumbar spine, total hip and 
femoral neck BMD after 12 months of treatment. Indeed, bone formation biomarkers increased, 
albeit transiently (for ~2 months), with bone resorption assays demonstrating a sustained reduction 
of bone turnover for the duration of the trial. These results are suggestive of an uncoupling of bone 
remodelling such that osteoclast inhibition does not lead to reduced bone formation [86]. Similar 
results were also obtained in a placebo-controlled trial of blosozumab, further confirming the 
efficacy of sclerostin inhibition[110]. In a subgroup analysis of the phase II RCT, investigators 
assessed bone strength at the LS and TH by quantitative computed tomography (QCT) in patients 
receiving placebo, open-ODEHO WHULSDUDWLGH  ȝJ GDLO\ RU URPRVR]XPDE (?PJ PRQWKO\
Reportedly, romosozumab achieved significantly greater gains in volumetric BMD and strength 
compared to teriparatide [111]. 
Romosozumab is the first agent of its class to have progressed to phase III trials with the proposed 
regimen of 210mg subcutaneously injected once monthly. The STRUCTURE trial investigating 
romosozumab vs. teriparatide in high-risk for fracture postmenopausal women transitioning from 
a bisphosphonate showed superiority of romosozumab in hip, lumbar and femoral neck BMD gains 
(2.6% vs -0.6%, 3.2% vs -0.2%, 9.8% vs. 5.4%, p for all comparisons <0.0001) [112]. Similar 
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significant hip, lumbar and femoral neck BMD gains in favour of romosozumab vs. placebo were 
noted in the BRIDGE study of men with osteoporosis[113]. 
In terms of the clinically relevant end-points of reduction in new vertebral fractures, romosozumab 
was superior to placebo in the ARCH and FRAME studies; results sustained after the addition of 
alendronate and denosumab respectively [114,115]. However, only ARCH showed a significant 
reduction in new vertebral, non-vertebral and hip fractures with romosozumab treatment. The 
discrepancy was cautiously attributed by the FRAME investigators to the recruitment of patients 
from a particular geographic region (Latin America) with a lower-than-expected non-vertebral 
fracture rate; effectively underpowering the trial for this end-point. Notably, a post-hoc analysis 
excluding patients from Latin America showed a significant reduction in new non-vertebral 
fractures favouring romosozumab[115]. 
Romosozumab was well-tolerated amongst recipients with discontinuation rates of 9.2%-11.2%, 
not significantly different from comparator group discontinuation rates whether active or 
placebo[112,114,115]. Regarding its safety, romosozumab inhibits sclerostin, whose secretion is 
confined mainly to the musculoskeletal system. However, the canonical Wnt signalling pathway 
is active in the cardiovascular and haematological systems [116±118]. Nonetheless, malignancy 
rates were similar in patients receiving romosozumab compared with control groups [114,115]. 
On the other hand, the signal with adjudicated serious adverse cardiovascular events is mixed; the 
FRAME study found no difference when romosozumab was compared to placebo (1.1% vs 1.2% 
respectively) [115], though the ARCH and BRIDGE studies showed numerically higher serious 
adverse cardiovascular events with romosozumab when compared to alendronate (2.5% vs 1.9%) 
and placebo (4.9% and 2.5%) respectively [113,114]. The ODWWHUXQGHUVFRUHGWKH)'$¶VUHTXHVW
for data from all three romosozumab trials prior to its final licensing decision.  
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Although the exact pathogenetic mechanism has yet to be clarified, the loss of the sclerostin 
inhibitory role on vascular calcification and the potential cardioprotective role of alendronate have 
been proposed [113,114]. Recently, Romosozumab, however, received approval in Japan for the 
treatment of osteoporosis in patients at high risk of fracture [i] 
[i] Pharmaceuticals and Medical Devices Agency Prescription Drug 
Database http://www.info.pmda.go.jp/go/pack/39994C7G1022_1_02/ 
Nonetheless, the aforementioned results show that sclerostin inhibition is a potential therapeutic 
target for osteoporosis. To date, no phase III trials with blosozumab are being conducted while 
BPS804 is now undergoing phase IIa trials for osteogenesis imperfecta after withdrawing from the 
ever-competitive osteoporosis market. 
 
3. Conclusions  
Existing anti-resorptive pharmacotherapy strategies for osteoporosis in women encompass 
bisphosphonates, denosumab and SERMS. The third generation of bisphosphonates employed to 
date for the treatment of osteoporosis (alendronate, ibandronate, zoledronate, risedronate) appears 
to be a reliable and cost-effective option. However, concerns have been raised with respect to their 
link to ONJ and AFFs. In addition, poor compliance has been reported owing to complex dosing 
regimen, while long-term efficacy (> 5 years) is yet to be established. Denosumab introduced a 
novel mechanism of action by inhibiting the interaction between RANK and its ligand, therefore 
reducing osteoclast maturation, survival and bone resorption. Dosing frequency and regimen 
simplicity have contributed to higher persistence and compliance rates, whereas recently published 
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data confirmed its unique characteristic of achieving a linear increase in BMD with no plateau 
being observed. Concerns regarding its association with ONJ and AFFs have not been confirmed 
as postmarket safety reports and higher-level evidence published failed to establish a causal 
relationship.  
Teriparatide and abaloparatide constitute the only approved osteoanabolic therapies currently used 
in the treatment of osteoporosis. They have a vital role in the management of high fracture risk 
patients and can be combined or precede anti-resorptive therapy to maximize their effect. One 
should note though their limitations, of the parenteral delivery route and high cost [76]. 
Refined knowledge regarding the molecular mechanisms and pathophysiology underlying bone 
remodelling, resulted in the development of state-of-the-art pharmacotherapies with dual action. 
Indeed, the efficacy of sclerostin inhibition was proved since both romosozumab and blosozumab 
achieved a significant increase in BMD in phase II studies. Concordant results were reported in 
phase III trials, where romosozumab - the only agent of its class to progress to late-stage clinical 
development ± augmented BMD in all skeletal sites measured. Recently Romosozumab received 
approval in Japan for the treatment of osteoporosis in patients at high risk of fracture. 
 
4. Expert Opinion 
 
Anti-resorptive drugs are used to suppress bone resorption and have spearheaded efforts to address 
the bone loss in osteoporosis, as well as the imbalance between bone formation and resorption. To 
date, four classes of agents are available: bisphosphonates, calcitonin, SERMS and denosumab. 
Two other drugs with unique mechanisms of action were either discontinued due to an unforeseen 
increase in stroke risk (odanacatib ± cathepsin K inhibitor) or currently awaiting )'$¶V ILQDO
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licensing decision (romosozumab ± sclerostin inhibitor that demonstrates both anabolic and anti-
resorptive properties). Osteoanabolic agents have also proven to be a beneficial therapeutic option 
and can be combined with other active agents, particularly in patients classified as high fracture 
risk. As evidenced by current trials, osteoanabolic agents exhibit maximal effect when they 
precede anti-resorptive therapy. Moreover, while the combination of teriparatide and 
bisphosphonates does not appear to offer any additional benefit compared with monotherapy, 
results from the concurrent use of denosumab and teriparatide have been encouraging as additional 
BMD gains have been observed. 
Despite the proven biochemical and clinical efficacy of established agents, the use of anti-
osteoporosis drugs has been on the decline [119,120]. Indeed, widely disseminated issues of 
osteonecrosis of the jaw [121], atrial fibrillation and cardiovascular adverse events [122,123] may 
have contributed to this decline. However, the risk-benefit ratio of anti-osteoporotic therapy 
remains favourable [124] with some animal studies also showing potential in reducing arresting 
aortic valve and coronary artery calcification [125,126]. Recently, advances elucidating the 
cellular and molecular regulatory mechanisms of bone remodelling have spearheaded efforts to 
develop and establish novel therapies [127,128]. 
Traditional molecular techniques and animal models have been proven effective in identifying 
potential targets for new therapies; notwithstanding, a downturn in the number of new osteoporosis 
drugs has been observed. Abaloparatide, gaining approval by the FDA in April 2017, has been the 
first new anabolic anti-osteoporotic medication in the US for nearly 15 years. Considering the 
major breakthroughs achieved in the field of modern genetics, there may be more efficient ways 
in the quest for novel drug targets. Indeed, a recent retrospective analysis concluded that 
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medications with direct genetic support demonstrated a significantly higher success rate across the 
drug developing pipeline [129]. 
With the available spectrum of anti-resorptive drugs, the overall burden of osteoporosis could 
potentially be alleviated. However, low public awareness in addition to adverse-effect profile and 
lack of long-term fracture data have contributed to poor compliance and to a decline in the use of 
anti-osteoporotic drugs. There is need of public health awareness and healthcare provider 
education regarding screening, prevention and treatment of osteoporosis, as well as accurate 
adverse effect description. We also need new pharmacological approaches that will fill unmet 
needs, specifically having a favourable safety profile, lacking the adverse effects of at AFFs and 
ONJ, employing a well-defined and simple dosing regimen and demonstrating long-term efficacy 
in reducing fracture rate or augmenting BMD. 
  
27 
 
 
Article Highlights:  
Anti-resorptive drugs have spearheaded efforts to address bone loss in osteoporosis, while 
osteoanabolic agents play a key role in high risk patients and combination therapy.  
 Abaloparatide, approved by the FDA in April 2017, has been the first new anabolic anti-
osteoporotic medication in the US for nearly 15 years.  
 Principles of existing antiosteoporotic medications in women, including mechanism of 
action, pharmacokinetics and safety profile are analysed. 
 An overview of the key clinical trials conducted in the field of antiresorptive and 
osteoanabolic agents to date is presented. 
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